US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease
29/04/2024 11:33
April 29 (Reuters) - The U.S. FDA has approved X4 Pharmaceuticals' XFOR.O drug to treat a rare genetic immunodeficiency disease, the company said on Monday. (Reporting by Christy Santhosh in Bengaluru; Editing by Shinjini Ganguli) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on X4 Pharmaceuticals
See all newsBrief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
X4 Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: X4 Pharmaceuticals Q2 Operating Expenses USD 25.197 Million
X4 Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule